BiotechTube
Indaptus Therapeutics

Indaptus Therapeutics

INDP
New York, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

INDP · Stock Price

USD 2.03-9.62 (-82.57%)
Market Cap: $4.4M

Historical price data

Overview

Indaptus Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for oncology and virology through its proprietary Decoy platform. The company's lead candidate, INDP-101, is in clinical trials for advanced solid tumors, designed to stimulate both innate and adaptive immunity. Its strategy centers on leveraging this multi-pathway approach to potentially enhance the efficacy of existing immunotherapies and address significant unmet medical needs in treatment-resistant cancers.

OncologyVirology

Technology Platform

The Decoy platform uses a systemically administered, killed, non-pathogenic bacterial vector engineered to deliver multiple pathogen-associated molecular patterns (PAMPs) to broadly activate both innate and adaptive immune responses.

Opportunities

The Decoy platform offers a novel approach to convert immunologically 'cold' tumors to 'hot,' potentially expanding the population responsive to checkpoint inhibitors in a large oncology market.
Positive Phase 1 data could validate the platform and attract partnership interest for combination studies.

Risk Factors

High risk of clinical failure for lead candidate INDP-101, limited cash runway necessitating dilutive financing, and intense competition in the innate immune activation space.
The company's valuation is highly sensitive to early-stage trial data.

Competitive Landscape

Faces competition from developers of intratumoral TLR/STING agonists, oncolytic viruses, cytokine therapies, and myeloid-targeting agents. Differentiation hinges on systemic delivery and multi-pathway activation, but this remains unproven clinically.

More companies in United States →